Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.
Thorac Cancer
; 7(4): 406-14, 2016 Jul.
Article
em En
| MEDLINE
| ID: mdl-27385982
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Systematic_reviews
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article